Case Report
Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
Table 1
Common adverse events and recommended management for lenvatinib treatment.
| Adverse events | CTCAE grade | CTCAE description | Management |
| Proteinuria | 1 | 0.15–1.0 g/24 h | None | 2 | >1.0–3.5 g/24 h | (i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h (ii) Consider consult nephrology | 3 | >3.5 g/24 h | (i) Hold lenvatinib until proteinuria resolves to ≤2.0 g/24 h (ii) Referral to nephrology | 4 | Nephrotic syndrome | (i) Discontinue lenvatinib permanently (ii) Referral to nephrology |
|
|
CTCAE, Common Terminology Criteria for Adverse Events; , gram; h, hours. |